shu-508 and Aortic-Valve-Stenosis

Ultrasound contrast media increase backscatter from blood, thus improving the signal-to-noise ratio. Potential clinical applications of intravenous ultrasound contrast are reviewed. Contrast enhancement of continuous wave Doppler is indicated when the native recordings are noisy and no complete envelope of the Doppler spectrum is obtained. In aortic stenosis several investigations showed good agreement between the gradient calculated from Doppler measurements and the results of cardiac catheterization. In mitral insufficiency maximum area of the regurgitant jet is a widely used parameter for estimation of the severity of the regurgitation. However, assessment of the maximum jet area may not be possible because of poor acoustic windows. Contrast enhancement provides complete display of the regurgitant jet in most of the patients. The diagnostic confidence of the Doppler investigation is further improved by the recording of the pulmonary venous flow, which can be recorded in most of the patients following contrast injection. Therefore contrast enhanced transthoracic Doppler is an alternative to transesophageal Doppler investigation in patients with poor transthoracic windows.

Topics: Aortic Valve Stenosis; Artifacts; Blood Flow Velocity; Contrast Media; Echocardiography, Doppler; Echocardiography, Doppler, Color; Humans; Injections, Intravenous; Mitral Valve Insufficiency; Polysaccharides

A multicenter study was carried out to evaluate the efficacy with which SHU 508A enhances left heart Doppler signals and improves the clinical quantification of valve disease.. Poor signal-to-noise ratio often limits the Doppler interrogation of left heart flows. This problem may be resolved by the enhancement of Doppler signals by an ultrasound contrast agent capable of pulmonary transmission, such as the recently developed SHU 508A.. Left heart contrast enhancement was tested for 1) continuous wave Doppler evaluation in 51 patients with aortic stenosis, 2) pulsed Doppler transthoracic evaluation of pulmonary venous flow in 85 patients, and 3) color Doppler evaluation of mitral regurgitation in 60 patients. Studies were performed immediately before and during the intravenous administration of SHU 508A (16 ml of 200 mg/ml) and compared with unenhanced transesophageal data in representative subsets of patients.. SHU 508A had no serious adverse effects. A significant increase in left heart Doppler signal intensity lasted for 30 to 300 s. The continuous wave Doppler velocity envelope was enhanced for all jets, but Doppler peak velocity was not altered in high quality baseline studies. However, Doppler contrast enhancement resulted in higher measured peak gradients (p < 0.001) in 29 patients with aortic stenosis who had poor quality baseline studies. This improved the overall correlation with invasive pressure measurements (r = 0.73 vs. r = 0.89, p < 0.01). The enhanced pulsed Doppler traces of transthoracic pulmonary venous flow allowed quantitative analysis in 92% patients (vs. 27% at baseline) and correlated well with peak velocities and velocity profiles obtained by transesophageal echocardiography (r = 0.91, p < 0.001). The enhanced color Doppler display of regurgitant jets increased jet area with a high interindividual variability (mean 276%), resulting in almost identical jet areas as unenhanced transesophageal values (r = 0.97, p < 0.001).. SHU 508A is a safe transpulmonary contrast agent that significantly enhances both spectral and color Doppler signals in the left heart. In specific patient subsets, the increase in signal-to-noise ratio improved the quantitative assessment of aortic stenosis, pulmonary venous flow and mitral regurgitation.

Topics: Aortic Valve Stenosis; Contrast Media; Echocardiography, Doppler; Echocardiography, Transesophageal; Female; Humans; Male; Middle Aged; Mitral Valve Insufficiency; Polysaccharides; Prospective Studies; Pulmonary Veins; Ventricular Function, Left

Topics: Aged; Albumins; Aortic Valve Stenosis; Contrast Media; Echocardiography, Doppler; Female; Fluorocarbons; Humans; Male; Middle Aged; Polysaccharides; Severity of Illness Index

Topics: Age Factors; Aged; Aortic Valve Stenosis; Contrast Media; Humans; Polysaccharides; Ultrasonography